DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2

Yanmin Zhang, Shuoxing Jiang, Dongdong Zhang, Xiaoguang Bai, Sidney Hecht, Shengxi Chen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In this study, we have prepared a DNA-affibody nanoparticle which mimics a antibody in its ability to specifically target the HER2 receptor. This nanoparticle has a smaller size (95 kDa) than the monoclonal antibody, trastuzumab (150 kDa) and at least two-fold greater activity toward BT474 cells than trastuzumab. The DNA in this nanoparticle structure has two functions, namely as a support to anchor two affibody molecules and as a vehicle to non-covalently bind multiple copies of a small molecule drug for drug delivery. Each DNA-affibody nanoparticle can bind ∼53 molecules of doxorubicin (DOX) to form a complex, which exhibits greater selectivity toward and inhibition of breast cancer cells overexpressing HER2 than doxorubicin does. As expected, the nanoparticle exhibits lesser inhibition of cells expressing HER2 at a low level. Thus, the nanoparticle represents a highly efficacious agent for inhibiting cancer cells which overexpress HER2, but with low toxicity toward normal cells.

Original languageEnglish (US)
Pages (from-to)573-576
Number of pages4
JournalChemical Communications
Volume53
Issue number3
DOIs
StatePublished - 2017

Fingerprint

DNA
Cells
Nanoparticles
Doxorubicin
Molecules
Monoclonal antibodies
Anchors
Drug delivery
Antibodies
Toxicity
Monoclonal Antibodies
Pharmaceutical Preparations
Trastuzumab

ASJC Scopus subject areas

  • Catalysis
  • Electronic, Optical and Magnetic Materials
  • Ceramics and Composites
  • Chemistry(all)
  • Surfaces, Coatings and Films
  • Metals and Alloys
  • Materials Chemistry

Cite this

DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2. / Zhang, Yanmin; Jiang, Shuoxing; Zhang, Dongdong; Bai, Xiaoguang; Hecht, Sidney; Chen, Shengxi.

In: Chemical Communications, Vol. 53, No. 3, 2017, p. 573-576.

Research output: Contribution to journalArticle

Zhang, Yanmin ; Jiang, Shuoxing ; Zhang, Dongdong ; Bai, Xiaoguang ; Hecht, Sidney ; Chen, Shengxi. / DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2. In: Chemical Communications. 2017 ; Vol. 53, No. 3. pp. 573-576.
@article{7026441dc57244049b4a0400ff34e128,
title = "DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2",
abstract = "In this study, we have prepared a DNA-affibody nanoparticle which mimics a antibody in its ability to specifically target the HER2 receptor. This nanoparticle has a smaller size (95 kDa) than the monoclonal antibody, trastuzumab (150 kDa) and at least two-fold greater activity toward BT474 cells than trastuzumab. The DNA in this nanoparticle structure has two functions, namely as a support to anchor two affibody molecules and as a vehicle to non-covalently bind multiple copies of a small molecule drug for drug delivery. Each DNA-affibody nanoparticle can bind ∼53 molecules of doxorubicin (DOX) to form a complex, which exhibits greater selectivity toward and inhibition of breast cancer cells overexpressing HER2 than doxorubicin does. As expected, the nanoparticle exhibits lesser inhibition of cells expressing HER2 at a low level. Thus, the nanoparticle represents a highly efficacious agent for inhibiting cancer cells which overexpress HER2, but with low toxicity toward normal cells.",
author = "Yanmin Zhang and Shuoxing Jiang and Dongdong Zhang and Xiaoguang Bai and Sidney Hecht and Shengxi Chen",
year = "2017",
doi = "10.1039/C6CC08495H",
language = "English (US)",
volume = "53",
pages = "573--576",
journal = "Chemical Communications (London)",
issn = "1359-7345",
publisher = "Royal Society of Chemistry",
number = "3",

}

TY - JOUR

T1 - DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2

AU - Zhang, Yanmin

AU - Jiang, Shuoxing

AU - Zhang, Dongdong

AU - Bai, Xiaoguang

AU - Hecht, Sidney

AU - Chen, Shengxi

PY - 2017

Y1 - 2017

N2 - In this study, we have prepared a DNA-affibody nanoparticle which mimics a antibody in its ability to specifically target the HER2 receptor. This nanoparticle has a smaller size (95 kDa) than the monoclonal antibody, trastuzumab (150 kDa) and at least two-fold greater activity toward BT474 cells than trastuzumab. The DNA in this nanoparticle structure has two functions, namely as a support to anchor two affibody molecules and as a vehicle to non-covalently bind multiple copies of a small molecule drug for drug delivery. Each DNA-affibody nanoparticle can bind ∼53 molecules of doxorubicin (DOX) to form a complex, which exhibits greater selectivity toward and inhibition of breast cancer cells overexpressing HER2 than doxorubicin does. As expected, the nanoparticle exhibits lesser inhibition of cells expressing HER2 at a low level. Thus, the nanoparticle represents a highly efficacious agent for inhibiting cancer cells which overexpress HER2, but with low toxicity toward normal cells.

AB - In this study, we have prepared a DNA-affibody nanoparticle which mimics a antibody in its ability to specifically target the HER2 receptor. This nanoparticle has a smaller size (95 kDa) than the monoclonal antibody, trastuzumab (150 kDa) and at least two-fold greater activity toward BT474 cells than trastuzumab. The DNA in this nanoparticle structure has two functions, namely as a support to anchor two affibody molecules and as a vehicle to non-covalently bind multiple copies of a small molecule drug for drug delivery. Each DNA-affibody nanoparticle can bind ∼53 molecules of doxorubicin (DOX) to form a complex, which exhibits greater selectivity toward and inhibition of breast cancer cells overexpressing HER2 than doxorubicin does. As expected, the nanoparticle exhibits lesser inhibition of cells expressing HER2 at a low level. Thus, the nanoparticle represents a highly efficacious agent for inhibiting cancer cells which overexpress HER2, but with low toxicity toward normal cells.

UR - http://www.scopus.com/inward/record.url?scp=85008941857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008941857&partnerID=8YFLogxK

U2 - 10.1039/C6CC08495H

DO - 10.1039/C6CC08495H

M3 - Article

VL - 53

SP - 573

EP - 576

JO - Chemical Communications (London)

JF - Chemical Communications (London)

SN - 1359-7345

IS - 3

ER -